Programme
Accelerate Alumni (Cohort 2)
Founded in
2013
Total funds raised
£52.3 million
Employees
101-250
Industry
Healthcare, pharma, biotech
Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible. Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.
Using Nuclera’s system scientists can automate construct screening to informoff-platform protein scale up, delivering reliable protein in-hand (µg-mg amounts) in less than 48 hours.
Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system.
Get in touch
Nuclera news
Healx | 1 August 2024
Nuclera awarded £1.1m Innovate UK funding
£790,000 FASST grant, in collaboration with DeepMirror, and £350k engineering biology grant awarded for development of eProtein discovery.